Zhou Xijian as chairman of the future development strategy of Hua Ren pharmaceutical is more clear-www.yeah.net

Zhou Xijian served as chairman of Huaren pharmaceutical future development strategy more clear hot column capital flows thousands thousand shares rating stocks the latest rating diagnosis simulated trading client Sina App: Live on-line blogger to guide you to say stocks contest off 60 million Securities Times reporter Cui Xiaoli in September 6th, has just completed a controlling stake in change of China Ren Pharmaceutical (300110) held in 2016 third extraordinary general meeting and the meeting of the board of directors, elected a new board of directors and senior management. Among them, the actual control of the company chairman Zhou Xijian served as president of the company, Zhou Xijian’s cousin Zhou Qiang, chairman of the company, the company chairman Liang Fuyou as honorary chairman. The company’s control rights and the board of directors have completed a smooth transition, and the future development strategy is more clear. In July this year, Huaren group will hold 174 million shares (Huaren pharmaceutical listed companies accounted for 26.46% of total equity), with 9.53 yuan of shares respectively to the investment and management of Hengfeng Yongyu Hengfeng Yongyu to transfer 110 million shares and 63 million 751 thousand and 400 shares. After the completion of the transfer, the shares held by Hua Ren group dropped from 42.60% to 16.14%, no longer the controlling shareholder of the company. Yongyu Hengfeng investment, Hengfeng Yongyu management will together hold 26.46% stake in the company, the company’s actual controller to change to Zhou Xijian. It is reported that Guangdong Yongyu and Hengfeng Yongyu health industry or for a long time in the future to maintain steady growth with confidence, the future will use the platform of listed companies to effectively integrate resources, optimize the listed company’s main business, improve the operating performance of listed companies, improve the quality of assets of listed companies, listed companies to enhance profitability and sustainable development ability. According to the announcement, the first half of 2016, the company achieved operating income of 5.8 billion yuan, an increase of 16.14%; attributable to owners of the parent company net profit of 3 million 61 thousand and 300 yuan, a year earlier than the 85.28% reduction. However, the company product sales and sales revenue of dialysis respectively over the same period last year growth of 53.37% and 44.06%, the number of peritoneal dialysis patients over the same period last year growth of 133.37% accept. Insiders said that the current development of China Ren pharmaceutical industry in the field of peritoneal dialysis can not be underestimated. The company official said, Huaren pharmaceutical is currently in the adjustment and development of strategic opportunities, the company will use asset and market advantage in the stable development of Hengfeng Yongyu, infusion, Liquor Dialysisintraperitoneus business at the same time, in order to Huaren nephropathy hospital as the carrier, through the medical service to promote PD product sales, promote the development of research and development and the pharmaceutical business, the construction company blood purification ecosystem field of the whole industry chain. In the development of new business, the company will continue to accelerate the pace of mergers and acquisitions or acquisitions, mergers and acquisitions in the fund industry will take the first step, continue to do bigger and stronger health industry. In addition, Huaren will vigorously develop medical investment management business, the company has the advantages of domestic and foreign medical resources, give full play to the listed company platform, combined with the existing construction of the hospital 2 nephropathy, and gradually to the general hospital, community hospital and other theory

周希俭出任董事长 华仁药业未来发展战略更加清晰 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 你说了算 上炒股大赛分掉6000万   证券时报记者 崔晓丽   9月6日,刚刚完成控股权变更的华仁药业(300110)召开2016年第三次临时股东大会及董事会会议,选举产生了新的董事会及高管层。其中,公司实际控制人周希俭出任公司董事长,周希俭的堂弟周强出任公司总裁,原董事长梁富友为公司名誉董事长。公司控股权及董事会完成了平稳过渡,未来发展战略规划愈加明晰。   今年7月,华仁集团将其持有的华仁药业1.74亿股股份(占上市公司总股本26.46%),以9.53元 股分别向永裕恒丰投资和永裕恒丰管理转让1.10亿股和6375.14万股。转让完成后,华仁集团持有华仁药业的股份比由42.60%降至16.14%,不再是公司控股股东。永裕恒丰投资、永裕恒丰管理将合计持有公司26.46%的股份,公司实际控制人变更为周希俭。   据悉,广东永裕和永裕恒丰对大健康产业或将在未来较长时间内保持稳定增长充满信心,未来将利用上市公司平台有效整合资源,持续优化上市公司主营业务,改善上市公司的经营状况,提高上市公司的资产质量,增强上市公司的盈利能力和可持续发展能力。   根据公告,2016年上半年,公司实现营业收入5.8亿余元,同比增长16.14%;归属母公司所有者的净利润306.13万元,比上年同期减少85.28%。但是,公司腹透产品销量和销售收入分别较去年同期增长53.37%和44.06%,接受腹膜透析的患者数量较去年同期增长133.37%。业内人士表示,华仁药业当前在腹膜透析领域的发展空间不容小觑。   公司相关负责人表示,华仁药业目前正处于调整和大发展的战略机遇期,公司将借助永裕恒丰的资产及市场优势,在稳定发展大输液、腹膜透析液业务的同时,以华仁肾病医院为载体,通过医疗服务促进腹透产品的销售,带动研发及医药商业的发展,构建公司血液净化领域全产业链生态圈。在新业务的拓展方面,公司还将持续加快收购并购的步伐,或将在产业基金并购方面迈出第一步,继续做大做强大健康产业。   另外,华仁还将大力发展医疗投资管理业务,利用公司已有的国内外优势医疗资源,充分发挥上市公司平台作用,结合现有筹建中的2家肾病专科医院,逐步向综合医院、社区医院及其它专科医院方向延伸,形成规模化的医疗投资管理集团,促进公司业务进一步向下游终端拓展延伸,夯实发展基础。 进入【新浪财经股吧】讨论相关的主题文章: